Expression of broadly expressed T cell markers such as CD3D, CD3E, and CD3G at day 16 of treatment, i.e., after 3 doses of tebentafusp, was increased but was not associated with tumor reduction or OS (data not shown). This evidence concerns the gene CD3G and neoplasm.